Efficacy and durability of nevirapine in antiretroviral-experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Harris, Marianne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Nevirapine; PI switch strategy; Salvage regimen

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASTHENIA; BULLOUS SKIN DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; LIPODYSTROPHY; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MYALGIA; NAUSEA; NOCTURIA; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SALVAGE THERAPY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT PLANNING; URINARY FREQUENCY; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY;

EID: 0141681326     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00008     Document Type: Conference Paper

References (17)

1. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced Human Immunodeficiency Virus disease who had previously failed combination nucleoside therapy. J Infect Dis 1998;177:1514-1520.
2. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a Human Immunodeficiency Virus Type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999;179:1375-1381.
3. + RNA after two years of therapy with ABT-378/ritonavir (ABT-378/r) in single protease inhibitor experienced patients [abstract P101]. AIDS 2000;14(suppl 4):S46.
4. Hicks C, Brun S, King M, et al. Lopinavir/ritonavir therapy in single protease inhibitor experienced patients: 144-week followup [abstract 220]. Presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infections, Athens, Greece, 2001.
5. Gulick RM, Smeaton LM, D'Aquila RT, et al. Indinavir, nevirapine, stavudine, and lamivudine for Human Immunodeficiency Virus-infected, amprenavir-experienced subjects: AIDS Clinical Trial Group Protocol 373. J Infect Dis 2001;183:715-721.
6. Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS 2001;15:117-119.
7. Montaner JSG, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001;15:61-69.
8. Harris M, Yip B, Hogg R, et al. Multiple drug rescue therapy (MDRT) with and without lopinavir/r (LPV/r) [abstract 114]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
9. Montaner JSG, Harris M, Harrigan R, Hogg R, Wood E. A compromise strategy for patients with multiple drug failure (letter). AIDS 2001;15:2470.
10. Viramune Product Monograph, Version 3.0, Boehringer Ingelheim International GmbH.
11. Murphy RL, Sommadossi J-P, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with Human Immunodeficiency Virus Type 1. J Infect Dis 1999;179:1116-1123.
12. Kaletra Product Information, Abbott Laboratories, North Chicago, IL, U.S.A., 2000.
13. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-810.
14. Raffi F, Bonnet B, Ferre V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma Human Immunodeficiency Virus Type 1 RNA. Clin Infect Dis 2000;31:1274-1278.
15. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-812.
16. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. JAIDS 2001;27:229-236.
17. Cotton G. Sustained virologic suppression in subjects switched from protease inhibitors to nevirapine [abstract WePeB4198]. Presented at the XIII International AIDS Conference, Durban, South Africa, 2000.